Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 758 of 6351
-
Microwave zaps prostate cancer while preserving normal function
Disease control OngoingThis clinical trial is to provide a minimally invasive treatment option in which the targeted prostate cancer tissue is killed by microwave only in the specific area of cancer "that should be treated for saving of life," while leaving a portion of the normal prostate tissue that …
Sponsor: Osamu Ukimura • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cheap antioxidant could replace costly drugs for Post-Transplant blood disorder
Disease control OngoingThis multicenter, prospective, single-arm clinical trial aims to evaluate the efficacy and safety of N-acetylcysteine (NAC) for treating Transplantation-Associated Thrombotic Microangiopathy (TA-TMA), a severe complication of hematopoietic stem cell transplantation characterized …
Phase 2/3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Virus and pill combo takes on recurrent brain tumors
Disease control Recruiting nowThe purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is contr…
Phase 2 • Sponsor: Ashish Shah • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
A 12-minute blood test may cut heart failure diagnosis delays
Diagnosis OngoingHeart failure is a serious condition that can be difficult to diagnose quickly when patients present to hospital with symptoms such as breathlessness. Delays in diagnosis may delay treatment and adversely affect patient outcomes. N-terminal pro-B-type natriuretic peptide (NT-proB…
Sponsor: University of Stirling • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
New drug aims to stop swelling attacks in hereditary angioedema
Disease control Recruiting nowProspective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pr…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Spinal stimulator aims to restore movement in paralyzed patients
Disease control Recruiting nowThe study aims to examine the plausible interventional mechanisms underlying the effects of epidural spinal cord stimulation.
Sponsor: Buddhist Tzu Chi General Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Engineered immune cells take on deadly brain tumors in first human trial
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatmen…
Phase 1 • Sponsor: Hideho Okada, MD, PhD • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New trial aims to save rectums in rectal cancer patients
Disease control Recruiting nowA phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage. The study investigates and may propose a comprehensive, stage-specific, multimodal appro…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Head-to-Head chemo battle: which regimen works better for hodgkin lymphoma?
Disease control CompletedThe goal of this phase III clinical trial was to make a direct head to head comparison between the chemotherapeutics; Bendamustine, Gemcitabine and Vinorelbine (BEGEV) and the the Gemcitabine, Dexamethasone and Cisplatin (GDP) regimens in the settings of relapsed and refractory c…
Phase 3 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New microwave zapper aims to destroy small liver tumors without surgery
Disease control Recruiting nowThe purpose of this study is to determine the technical success rate of creating a safety margin of 5 mm or more including the tumor by performing image-guided percutaneous microwave thermal therapy using a microwave generator and antenna developed by StarMed for the treatment of…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug pegtibatinase tested for rare metabolic disorder over two years
Disease control By invitation onlyThe goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of blinded treatment in the Phase 3 …
Phase 3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can weight loss drugs boost heart function in obese heart failure patients?
Disease control Recruiting nowThe benefit of weight loss in patients with obesity and heart failure with reduced ejection fraction (HFrEF) is controversial. Semaglutide has shown cardiovascular (CV) risk-reduction and impact on CV risk factors including overweight, dysglycaemia and hypertension in subjects wi…
Phase 2/3 • Sponsor: Jens D Hove, MD,PHD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double attack on lymphoma: antibody plus CAR-T combo shows promise
Disease control OngoingThe aim of this study was to analyze the safety and efficacy of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's (B-NHL) lymphoma. The main questions it aims to answer: 1. The safet…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a quick second drug boost stroke recovery?
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
One visit, two shots: study tests combining RSV and COVID vaccines for seniors
Vaccine CompletedThis study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 08:06 UTC
-
New gene therapy trial hopes to tame rare metabolic disease in kids
Disease control Recruiting nowPhase I, open-label, single-arm, single-dose, trial of VGM-R02b (gene replacement therapy) in patients with Glutaric Acidemia Type I (GA-I) who meet enrollment criteria and are genetically confirmed by GCDH gene mutation. 1 to 3 patients aged≤ 6 years at the time of screening wil…
Phase 1 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo shows promise for Tough-to-Treat skin cancer
Disease control OngoingStage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + t…
Phase 3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
RSV vaccine shows promise for High-Risk younger adults
Vaccine CompletedThe aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and ab…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 07:51 UTC
-
New pill targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThe study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TS…
Phase 1/2 • Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
A new Fast-Track HIV care model aims to Re-Engage those lost to care
Disease control OngoingThe main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The study will also assess the acceptability, appropriateness, feasibility, and sustainability of the ACCELERATE model of care. The ACCELER…
Phase 4 • Sponsor: University of Missouri-Columbia • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC